Curative Liver and Kidney Transplantation for Ongoing Symptoms of Acute Intermittent Porphyria and End‐Stage Kidney Disease
Case Reports in Transplantation · 2026-01 · 2026 (1)
DOI: 10.1155/crit/2931133 ↗Abstract
Acute intermittent porphyria (AIP), the most common of the acute hepatic porphyrias, is a rare autosomal dominant disorder with variable penetrance resulting from pathogenic variants of the third enzyme in the heme biosynthetic pathway. Most heterozygotes never develop symptoms; some have infrequent acute attacks of multiple neuropathic manifestations including abdominal pain and motor weakness, and a few experience repeated debilitating attacks over many years. Long‐term complications may include end stage renal disease (ESRD), treated by dialysis or kidney transplantation, and liver cancer. Acute attacks are treated with intravenous hemin and may be prevented by prophylactic hemin infusions or givosiran, a long‐acting interfering RNA therapeutic. Liver transplantation is curative when medical therapies are inadequate. Simultaneous liver‐kidney transplantation (SLKT) has been reported to be beneficial in patients with ongoing active AIP and chronic kidney disease, but experience is limited. We report the case of a woman with AIP manifested by frequent recurrent attacks and chronic symptoms starting at age 17 and progressive renal disease beginning at age 28. Attacks were partially prevented by prophylactic hemin from age 29–42 and then givosiran from age 42–47. SLKT at age 47 restored renal function and resolved all biochemical and clinical manifestations of AIP. This experience supports SLKT as a suitable option for patients with ESRD and ongoing manifestations of AIP that respond incompletely to pharmacologic therapies.
EUVIMED